Lassere MND - Search Results

1

Bias, coverage, and asymptotic behaviour of random effects meta-analysis: a clinically driven simulation study.

Johnson K, Hayen A, Lassere MND, Mengersen K. Johnson K, et al. Among authors: lassere mnd. JBI Evid Implement. 2020 Dec;18(4):355-367. doi: 10.1097/XEB.0000000000000227. JBI Evid Implement. 2020. PMID: 33570319

2

Recent rheumatoid arthritis clinical trials using radiographic endpoints--updated research agenda.

Strand V, Lassere M, van der Heijde D, Johnson K, Boers M. Strand V, et al. J Rheumatol. 2001 Apr;28(4):887-9. J Rheumatol. 2001. PMID: 11327271 Review.

3

Foundations of the minimal clinically important difference for imaging.

Lassere MN, van der Heijde D, Johnson KR. Lassere MN, et al. J Rheumatol. 2001 Apr;28(4):890-1. J Rheumatol. 2001. PMID: 11327272

4

Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials.

Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Lassere MN, et al. J Rheumatol. 2001 Apr;28(4):892-903. J Rheumatol. 2001. PMID: 11327273

5

Robustness and generalizability of smallest detectable difference in radiological progression.

Lassere MN, van der Heijde D, Johnson K, Bruynesteyn K, Molenaar E, Boonen A, Verhoeven A, Emery P, Boers M. Lassere MN, et al. J Rheumatol. 2001 Apr;28(4):911-3. J Rheumatol. 2001. PMID: 11327275

6

The power of the protocol.

Lassere M, Johnson K. Lassere M, et al. Lancet. 2002 Nov 23;360(9346):1620-2. doi: 10.1016/S0140-6736(02)11652-7. Lancet. 2002. PMID: 12457782 No abstract available.

7

Challenges and progress in adverse event ascertainment and reporting in clinical trials.

Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM. Lassere MN, et al. J Rheumatol. 2005 Oct;32(10):2030-2. J Rheumatol. 2005. PMID: 16206364 Review.

8

Generic patient self-report and investigator report instruments of therapeutic safety and tolerability.

Lassere MN, Johnson KR, Van Santen S, Carlton K, Rappo J, Michael R, Kirwan JR, Edmonds JP. Lassere MN, et al. J Rheumatol. 2005 Oct;32(10):2033-6. J Rheumatol. 2005. PMID: 16206365

9

Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.

Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, de Wit M, Edwards IR, Fries JF, Furst DE, Kirwan JR, Tugwell PS, Woodworth TG, Brooks PM. Lassere MN, et al. J Rheumatol. 2005 Oct;32(10):2037-41. J Rheumatol. 2005. PMID: 16206366

10

Clinical trials report card.

Johnson K, Lassere M. Johnson K, et al. N Engl J Med. 2006 Mar 30;354(13):1426-9; author reply 1426-9. N Engl J Med. 2006. PMID: 16575953 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters